Quantum Partners with Ingenu CRO for Study on MS Disease Progression

Quantum BioPharma Ltd, a company focused on developing a range of new assets and biotechnology solutions, has revealed that its subsidiary, HUGE Biopharma Australia Pty Ltd, has partnered with Ingenu CRO Pty Ltd to carry out a clinical study on tracking disease progression in primary progressive multiple sclerosis (MS)  patients. This research will help in conducting a upcoming phase 2 clinical trial involving Lucid-21-302.

“We are very pleased to be working with Ingenu CRO to conduct this observational study in patients with multiple sclerosis. This is an important study which advances our multiple sclerosis research programme and moves us closer to initiating a phase 2 clinical trial with Lucid-21-302,” said Dr. Andrzej Chruscinski, vice-president, scientific and clinical affairs at Quantum Biopharma.

Quantum BioPharma focuses on creating a range of cutting-edge products and biotech treatments for difficult neurodegenerative, metabolic, and alcohol misuse disorders, with various drug candidates in development.

Quantum BioPharma is dedicated to the research and development of Lucid-MS through its subsidiary, Lucid Psycheceuticals Inc. Lucid-MS, a patented novel substance, has been demonstrated to stop and undo myelin deterioration, the primary cause of multiple sclerosis, in preliminary animal studies.